Humanized Mouse Models of HIV Infection

Paul W. Denton[*] and **J. Victor Garcia**

Abstract

Because of the limited tropism of HIV, *in vivo* modeling of this virus has been almost exclusively limited to other lentiviruses such as SIV that reproduce many important characteristics of HIV infection. However, there are significant genetic and biological differences among lentiviruses and some HIV-specific interventions are not effective against other lentiviruses in non-human hosts. For these reasons much emphasis has recently been placed on developing alternative animal models that support HIV replication and recapitulate key aspects of HIV infection and pathogenesis in humans. Humanized mice, CD34$^+$ hematopoietic progenitor cell transplanted immunodeficient mice and in particular mice also implanted with human thymic/liver tissue (BLT mice) that develop a functional human immune system, have been the focus of a great deal of attention as possible models to study virtually all aspects of HIV biology and pathogenesis.

Humanized mice are systemically reconstituted with human lymphoid cells offering rapid, reliable and reproducible experimental systems for HIV research. Peripheral blood of humanized mice can be readily sampled longitudinally to assess reconstitution with human cells and to monitor HIV replication permitting the evaluation of multiple parameters of HIV infection such as viral load levels, CD4$^+$ T cell depletion, immune activation, as well as the effects of therapeutic interventions. Of high relevance to HIV transmission is the extensive characterization and validation of the reconstitution with human lymphoid cells of the female reproductive tract and of the gastrointestinal tract of humanized BLT mice that renders them susceptible to both vaginal and rectal HIV infection. Other important attributes of all types of humanized mice include: 1) their small size and cost that make them broadly accessible; 2) multiple cohorts of humanized mice can be made from multiple human donors and each cohort has identical human cells, permitting control of intragenetic variables; 3) continuous *de novo* production of human immune cells from the transplanted CD34$^+$ cells within each humanized mouse facilitates long term experiments; 4) both primary and laboratory HIV isolates can be used for experiments; and 5) in addition to therapeutic interventions, rectal and vaginal HIV prevention approaches can be studied. In summary, humanized mice can have an important role in virtually all aspects of HIV research including the analysis of HIV replication, the evaluation of HIV restriction factors, the characterization of successful biomedical HIV prevention strategies, the evaluation of new treatment regimens and the evaluation of novel HIV eradication strategies.

Introduction – Why humanized mice?

According to WHO-AIDS there are 33 million HIV infected people worldwide [1]. Treating these infected persons and preventing new transmissions are cornerstones of the biomedical

[*]To whom correspondence should be addressed: Division of Infectious Diseases, UNC Center for AIDS Research, University of North Carolina School of Medicine, Genetic Medicine Building 2044, Chapel Hill, NC 27599-7042, Tel: 919-843-9555, Fax: 919-966-6870, pdenton@med.unc.edu.

response to HIV infection. A safe and efficacious vaccine would be the most cost-effective way to control the HIV pandemic, but such a vaccine is not yet available for clinical implementation. Therefore, there is an urgent need for improved, potentially curative HIV therapeutic regimens that can be universally accessed and a need for the rapid implementation of biomedical prevention approaches to stop the spread of HIV/AIDS. Patient-based research to develop these interventions requires extensive preclinical evaluations in robust, reproducible and reliable models of HIV infection. Cell culture systems and *ex vivo* tissue explants have been used extensively to model HIV infection [2-5]. Explants in particular have been used by several groups because of their inherent increased complexity that includes both epithelium and HIV target cells. However there are many aspects of HIV infection that can be best modeled using *in vivo* models. For example, the entire dynamics of HIV transmission and disease progression in humans is extremely complex and cannot be replicated *in vitro*. Mucosal and peripheral organ systems all play important roles in transmission, replication and pathogenesis. The ability to model the complexity of HIV disease makes animal models the most versatile experimental systems for the evaluation of HIV transmission, *in vivo* replication, pathogenesis mechanisms, novel therapies and prevention agents.

HIV replication is restricted to humans and chimpanzees, but HIV only causes AIDS in humans. This strict species tropism has severely constrained *in vivo* experimentation [6]. As alternatives, multiple other lentiviruses have contributed to our understanding of HIV/AIDS when they infect their natural or related hosts as models of HIV infection. For example, wild chimpanzees and gorillas are naturally infected with the predecessor viruses to HIV, SIV_{cpz} and SIV_{gor} [7, 8]. Additionally, increased mortality and AIDS-like immunopathology has been documented in wild chimpanzees infected with SIV_{cpz} [9]. These findings offer critical insights into the pathogenic potential of the viruses in these great ape populations; however, great apes are generally unavailable for HIV research. Therefore, alternative model systems have been sought such as lentiviruses capable of causing immunosuppression following infection of non-human primates (NHP), cats and cattle. These viruses include simian immunodeficiency virus (SIV), SIV/HIV chimeric viruses (SHIV), feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV), respectively [6, 10-15]. Other lentiviruses that have also been evaluated as HIV models lead to immunoproliferation in horses, sheep and goats. These are equine infectious anemia virus (EIAV), ovine lentivirus (OvLV) and caprine arthritis-encephalitis virus (CAEV), respectively [15]. In particular, the NHP-SIV and NHP-SHIV models have contributed greatly to our understanding of HIV infection. However, the number of NHP available for research (especially females) is limited and the costs associated with NHP studies are high. It should also be noted that many biomedical interventions for HIV prevention and therapy are HIV-specific and that HIV has genetic and biological differences from SIV and SHIV. Those interventions that inhibit HIV specifically cannot be evaluated using NHP-SIV or NHP-SHIV models [6]. Therefore, *in vivo* infection models that utilized HIV itself are needed and humanized mice have been shown to help fulfill this need.

The term "humanized mice" has been applied to a variety of mouse models: (a) mice that have a single or multiple human transgene(s) in an otherwise wild-type animal, (b) immunodeficient mice transplanted with human cells or implanted with normal or diseased human tissues, (c) CD34[+] hematopoietic progenitor cell engrafted immunodeficient mice and (d) various combinations of a, b, and c [16-22]. The focus of this review is on humanized mouse models of HIV infection generated by CD34[+] hematopoietic progenitor cell transplantation. In these mice, CD34[+] cells generate *de novo* human immune cells capable of supporting *in vivo* HIV replication. One important point that needs to be emphasized is whereas most lymphoid cells develop in bone marrow, T cells do not. Thymic progenitors exit the bone marrow and migrate to the thymus because T cells require the

special microenvironment present in the thymus to develop. In CD34+ transplanted mice this takes place in the mouse thymus [23-26]. However, BLT mice represent the only system where this takes place in the implanted human thymic organoid [27, 28]. Thus in BLT mice human T cells are generated in the context of human thymic stroma where they are specifically educated in the context of human leukocyte antigen (HLA). Together, these relatively recently described humanized mouse models represent rapid, reliable and reproducible experimental systems for HIV research as evidenced by their extensive use since parenteral HIV infection of these mice was first reported five years ago (Table 1) and [29, 30].

Why humanized mice? Their relative simplicity, small size and cost make humanized mice broadly accessible for *in vivo* HIV infection studies. It is important to note that despite their overall similarities, there are significant differences between humanized mouse models and that each model has its own advantages and limitations, both of which are addressed throughout this text. However, a key area where further improvements are needed is in the development of robust and sustained immune responses across different platforms (Table 1). Moreover, many organ pathologies caused by HIV are not perfectly recreated because *in vivo* reconstitution is limited to the progeny of the transplanted human CD34$^+$ cells. One important exception is the BLT model where human thymic pathology can be studied in the context of human thymic epithelium. BLT mice exhibit robust and sustained levels of human cells in their gastrointestinal and female reproductive tracts, whereas differences in the levels and uniformity of reconstitution of these important tissues between humanized mice models using only CD34$^+$ transplants can result in different experimental outcomes. Other factors to consider when choosing humanized mice for HIV research is the relatively shorter life-span of mice (compared to NHP and humans), the heightened susceptibility of immunocompromised mouse stains (especially after irradiation) to opportunistic infections and death unrelated to HIV infection and the differences in husbandry techniques used in different animal facilities. Nevertheless, specific advantages of humanized mice for HIV research include the ability to generate multiple cohorts of humanized mice from multiple human donors. Each cohort from a single human donor is composed of individual animals with genetically identical human cells, permitting control of intragenetic variables. Continuous *de novo* production of human immune cells from engrafted CD34$^+$ cells within each humanized mouse enables longitudinal experiments. Importantly, humanized mice do not require that a surrogate virus be used for infection studies. Humanized mice can be used for *in vivo* HIV infection studies because they support transmission and replication of laboratory adapted and primary HIV isolates. Finally, HIV prevention interventions can be studied in humanized mice because they are susceptible to multiple routes of HIV transmission.

An overview

Since the early stages of the AIDS epidemic it was realized that small animal models for HIV research would permit a wide range of studies of HIV pathogenesis, prevention and therapy. The challenge noted was that rodent cells are fully refractory to HIV: HIV cannot bind and enter rodent cells, as it does human cells, unless those cells express the primary HIV receptor and a co-receptor molecule (human CD4 and human CCR5 or CXCR4, respectively) [31, 32]. However, even when these critical molecules are expressed on the surface of mouse cells and successful viral entry occurs, HIV encounters numerous additional blocks to its replication in rodent cells [33, 34]. Since HIV will typically replicate robustly in human cells several groups developed xenograft models by placing human cells in mice such that HIV could replicate *in vivo* [35, 36]. Two of these mouse models, designated severe combined immunodeficient-human (SCID-hu) thy/liv and SCID-hu PBL, have been extensively utilized to study viral cytopathic effects, for the evaluation of antiviral

drugs and, to a lesser extent, to evaluate potential vaccine approaches [37-42]. These models are not optimal for the study of anti-HIV human immune responses, pathogenesis or for mucosal HIV transmission [18, 43, 44]. In contrast, some of the more recently described CD34[+] cell transplanted humanized mice have been shown to be well suited for these types of *in vivo* studies.

Common to all CD34[+] cell transplanted humanized mouse models is the use of one of several available immunodeficient mouse strain that are capable of engrafting and sustaining human hematopoietic cells [44]. The history and characteristics of mouse strains used for generating humanized mice have been recently described in great detail [44]. The three strains of immunodeficient mice that are most frequently used to generate humanized mice, as reviewed here, are: (1) *Non-obese diabetic/SCID (NOD/SCID)*, (2) *Rag2$^{null}\gamma c^{null}$* and (3) *NOD/SCIDγc^{null}* (Table 2). (1) *NOD/SCID* mice [*NOD/Shi-scid*; Central Institute for Experimental Animals; Kanagawa, Japan and *NOD/LtSz-scid/scid*; The Jackson Laboratory; Bar Harbor, Maine] have reduced mouse NK cell levels and are devoid of mouse T and B lymphocytes [45, 46]. (2) *Rag2$^{null}\gamma c^{null}$* mice (*BALB/c-Rag2$^{null}\gamma c^{null}$*; Centre National de la Recherché Scientifique; Orleans, France) are frequently referred to as double knockout or DKO mice (the term used herein). DKO mice lack expression of the interleukin 2 receptor common gamma chain (γc^{null}) and are completely deficient in mouse T, B, and NK cells [47]. Humanized DKO mice are sometimes referred to as human immune system (HIS) mice or Rag-hu mice [26, 30, 48, 49]. (3) There are two *NOD/SCIDγc^{null}* strain variants originating from the NOD/SCID mice introduced above. *NOD/Shi-scidγc^{null}* mice are referred to as NOG mice (Central Institute for Experimental Animals; Kanagawa, Japan), whereas *NOD/LtSz-scid/scidγc^{null}* mice are called NSG mice (The Jackson Laboratory; Bar Harbor, Maine). NOG and NSG mice also lack expression of the interleukin 2 receptor common gamma chain (γc^{null}) and are completely deficient in mouse T, B, and NK cells. These two similar strains differ in their gamma chain mutations. In NOG mice the gamma chain is truncated within the intracellular signaling domain while the targeted gamma chain mutation in NSG mice is a complete null phenotype [44, 50, 51]. While these are not the only immunodeficient strains utilized to generate CD34[+] cell transplanted mice [52-54], the stains described above account for the CD34[+] cell transplanted mice used in HIV research to date (Table 1).

There are significant differences observed in the levels of engraftment with human CD34[+] hematopoietic progenitor cells and in the levels of repopulation with CD34-derived human lymphoid cells between different immunodeficient mouse strains. *NOD/SCID* mice engraft with human CD34[+] cells better than *SCID* mice due to their lower levels of mouse NK cells [45, 46]. Better human engraftment in NOG and NSG mice compared to their two *NOD/SCID* parent strains has been reported [55]. Female NSG mice have also been reported to engraft somewhat better than NSG males [56, 57]. This is a remarkable phenotype that could possibly be exploited to further increase cohort sizes by using reduced numbers of CD34[+] cells for the bone marrow transplants in NSG female mice. To generate CD34[+] cell transplanted humanized mice, individual mice are typically preconditioned (i.e. gamma radiation exposure or treatment with busulfan) to create a niche in the bone marrow for the transplanted human CD34[+] hematopoietic progenitor cells [25, 58-62]. Human CD34[+] cells for transplantation are typically derived from umbilical cord blood, fetal liver or granulocyte colony-stimulating factor mobilized peripheral blood [63]. One important consideration for the use of cord blood derived CD34+ cells is their relatively low abundance, limiting the number of mice that can be generated from a single sample. However, some investigators have overcome this limitation by combining cord blood CD34[+] cells from separate donors for transplantation [64, 65]. It should be noted that in the case of humanized BLT mice each animal receives both transplanted CD34[+] cells and implanted tissues from the same donor [27, 28]. Regardless of the source of CD34[+] cells, engraftment with hematopoietic

progenitor cells results in a lifelong (8-24 months - depending on the mouse strain and humanization strategy utilized; Table 2) supply of human immune cells in transplanted humanized mice [44, 66].

The nature of humanized mice, which essentially harbor a complete human immune system, provides biomedical researchers with affordable, accessible and flexible experimental platforms for *in vivo* modeling of human diseases and for the development and evaluation of methods to counter these diseases. In this regard, CD34[+] cell transplanted humanized mice have been primarily used to successfully model a variety of human specific infectious diseases. However, the applications of humanized mice have not been limited solely to human infections. Other diseases and conditions that have been successfully modeled in humanized mice include type 1 diabetes [67], inflammatory arthritis [68], tumor burden control [69], human breast tumor growth [54] and idiopathic nephrotic syndrome [70]. Besides HIV, human infectious diseases modeled in humanized mice include Epstein-Barr virus [71-74], hepatitis C virus [75], human cytomegalovirus [76], herpes simplex virus type 2 (HSV-2) [77], live attenuated influenza vaccines [52], *Salmonella typhi* [78-80], sepsis [81] and dengue virus [82-87]. Additionally, auto-regulatory lentiviral vectors that permit doxycycline-inducible gene expression in human hematopoietic cells have been successfully utilized in humanized mice as a model for inducible genetic therapeutic strategies being considered for humans [88].

BLT Mice—As indicated above, BLT mice are the only model in which human T cells can develop in the context of a human thymic microenvironment. This significant difference sets this model apart and merits special consideration and description. In contrast to the other humanized mouse models discussed in the following section, in BLT mice implanted human tissue develops into a *bona fide* human thymus where human thymocytes are educated and mature into a diverse repertoire of functional HLA-restricted T cells [28, 89]. Furthermore, the fact that human T cells were educated in a human thymus could be a contributing factor in the extensive and reproducible human reconstitution of the BLT mouse gastrointestinal tract [90, 91].

Generation of BLT mice includes a Bone marrow graft accomplished by the transplant of fetal liver-derived CD34[+] hematopoietic progenitor cells into preconditioned *NOD/SCID* or NSG mice previously implanted with autologous fetal Liver and Thymus tissue [27, 28, 92-95]. Human immune cells including T, B, natural killer, myeloid and dendritic cells are found throughout BLT mice. Beyond peripheral blood reconstitution with human cells, BLT mouse tissues have been shown to reconstitute with high levels of human immune cells throughout the body including in the human thymic organoid, bone marrow, spleen, lymph nodes, liver, lungs, small and large intestines and the female reproductive tract [27, 28, 89-95]. In BLT mice both the intraepithelial and lamina propria compartment of the small and large intestines are populated with human T lymphocytes [90, 91]. The exquisitely specific nature of the human reconstitution of the BLT mouse small intestine is highlighted by the fact that CD8[+]CD4[+] T lymphocytes in NOD/SCID BLT mice were shown to exhibit a human gut specific surface phenotype [91]. Specifically, the intestinal CD8[+]CD4[neg] T cells express the typical alpha-beta heterodimer on their surface, but the CD8[+]CD4[+] T cells express a CD8 molecule composed of an alpha-alpha homodimer which is a known human gut cell surface phenotype [96, 97]. The BLT mouse female reproductive tract is also well reconstituted with human immune cells [90]. The vagina, ectocervix, endocervix and uterus of BLT mice have been shown to harbor many human T cells, including CD4[+] T cells. In addition, each of these regions of the BLT female reproductive tract contains human monocyte/macrophages and human dendritic cells [90]. Thus, BLT mice are fully reconstituted with multiple human hematopoietic lineages throughout the body, including critical mucosal surfaces such as the intestines and female reproductive tract.

Human immune responses in BLT mice are relatively robust and exquisitely specific, which is in contrast to the limited immune responses described below for CD34[+] cell transplanted DKO/NOG/NSG mice. For example, 2,4-dinitrophenyl hapten-keyhole limpet hemocyanin (DNP23-KLH) immunization in BLT mice results primarily in DNP specific IgG1 and IgG2, with minimal DNP-specific IgG3 and no DNP-specific IgG4 detected [94]. This is quite similar to the IgG subclass distribution in humans after KLH immunization in which IgG3 antibodies are less frequent and IgG4 antibodies are very slow to develop [94, 98]. Other robust human immune responses in BLT mice include xenograft rejection, T-cell dependent antibody development, anti-viral responses, specific superantigen responses and delayed type hypersensitivity (DTH) responses [27, 28, 93-95]. In addition, discussed below is the fact that BLT mice generate the most extensive human immune responses against HIV of any humanized mouse model tested to date.

CD34[+] cell transplant only mice—As indicated above, in contrast to BLT mice, CD34[+] cell transplanted DKO/NOG/NSG mice do not contain a human thymic microenvironment where human T cells can develop. Rather in each of these models, human T cells are generated in the mouse thymus [23-26]. The lack of HLA restriction could have major implications in the potential for developing robust human immune responses in CD34[+] cell transplanted DKO/NOG/NSG mice.

Despite this limitation, CD34[+] cell transplanted DKO/NOG/NSG mice have been extensively utilized in HIV research (Table 1). The primary method for generating these mice is to transplant CD34[+] cells by either an intrahepatic or intravenous injection into newborn DKO, NOG or NSG mice (Table 1). This technique for the generation of humanized mice was first described by Traggiai, *et al.* and Gimeno, *et al.* and has been widely adopted [25, 26, 48, 99-106]. In addition, CD34[+] cells have also been transplanted into adult NOG and NSG mice resulting in similar levels of systemic human reconstitution [23, 57, 58, 62, 107-112]. In each of these instances, the transplanted immunodeficient mouse becomes systemically populated with human immune cells originating from the mouse's bone marrow. Human immune cells including T, B, natural killer, myeloid and dendritic cells are found throughout CD34[+] cell transplanted DKO/NOG/NSG mice. Beyond peripheral blood reconstitution with human cells, tissues from these mice have been shown to harbor human immune cells in the thymus, bone marrow, spleen, lymph nodes, liver, lungs [23, 25, 26, 48, 57, 58, 62, 99, 100, 102-112]. Reconstitution of the intestines and female reproductive tracts of CD34[+] cell transplanted NOG and NSG mice has not been addressed in the literature; however, immunofluorescence analysis of CD34[+] cell transplanted DKO mice showed the presence of human immune cells in the vagina, large intestine and rectum of these mice [113]. A different research group also addressed the question of humanization of the female reproductive tract of CD34[+] cell transplanted DKO mice and reported a very different result [77]. Their report indicated that the vaginal tract of these mice did not harbor human immune cells unless stimulated by either HSV-2 vaccination or vaginal infection with replication competent HSV-2. Interestingly, the human cells that were detected in the vaginal tissue of these mice following HSV-2 challenge were CD8[+] T cells and CD3[-]CD56[+] NK cells. Notably, no human CD4[+] T cells were found [77]. Two additional research groups examined the human cell reconstitution of the gut from CD34[+] cell transplanted DKO mice. One group found that 2 of 6 mice were reconstituted with greater than 5% human lymphocytes when they examined the entire intestine using flow cytometry [114]. The other group reported that CD34[+] cell transplanted DKO harbor no to very few human immune cells in their small and large intestines after examining 14 mice by immunohistochemistry and 3 by flow cytometry [115]. Therefore, it is clear that human cells can migrate into the female reproductive tract and intestines of CD34[+] cell transplanted DKO mice. However, what is uncertain at this point is the extent to which the human immune cells are able to reconstitute these important mucosal sites of HIV

transmission in a reproducible and robust manner. It should be noted that the differences in results obtained between these four research groups while characterizing CD34[+] cell transplanted DKO mice could be due to several factors including: use of different protocols for the handling and/or culturing of CD34[+] cells prior to injection, differences in the numbers of CD34[+] cells transplanted among research groups, age at which mice were tested for mucosal humanization, and perhaps other unknown factors. Overall, based on these reports the humanization of the intestines and female reproductive tract of CD34[+] cell transplanted DKO mice appears sporadic and inconsistent [77, 113-115]. These discordant results regarding the intestinal humanization in this model might help explain to a certain extent the differences reported in mucosal HIV transmission in humanized DKO mice (see below).

The functional capacity of the human immune systems in variants of CD34[+] cell transplanted DKO/NOG/NSG mice has been evaluated by multiple research groups. The results have indicated that both functional and dysfunctional human lymphocytes and NK cells can be identified in these systems, suggesting that further improvement will be needed before these models can be effectively used to evaluate human immune responses [25, 26, 58, 99, 104, 111, 112, 116, 117]. Therefore, different approaches have been used to improve the humanization and immune function in these mice. Exogenous human IL-15 and human Flt-3/Flk-2 ligand expression in CD34[+] cell transplanted DKO mice was reported to improve NK and myeloid cell levels and function [48, 103, 109]. Similarly, exogenous IL-7 was evaluated for its ability to enhance human thymocyte development and lymph node maturation in these mice [106]. While this work highlighted the importance of human IL-7 in human T cell development within CD34[+] cell transplanted DKO mice, the IL-7 treatments did not improve homeostasis of peripheral T cells in this system [106]. In addition to treatment with exogenous factors for improved immune reconstitution and immune function, there have been efforts to generate transgenically modified immunodeficient mice. CD34[+] cell transplanted homozygous knockin DKO mice that express human thrombopoietin (TPO) (in place of mouse TPO) maintained peripheral human reconstitution of human lymphocytes for several months beyond what was observed to occur in DKO mice without human thrombopoietin. These human TPO expressing mice exhibit higher levels of human granulocytes, but human T cell levels were very low in these mice [118]. When human CD34[+] cells were transplanted into a modified NSG mouse strain that expresses human stem cell factor (SCF), granulocyte macrophage colony stimulating factor (GMCSF) and interleukin 3 (IL-3) (called NSG-SGM3 mice), these mice generated robust human myeloid lineage reconstitution plus an abnormally high number of CD4[+] T cells throughout multiple organs examined. The observed CD4[+] T cells increase appeared to be due to higher numbers of functional CD4[+]FoxP3[+] T regulatory cells, not T helper subsets [119]. In order to improve the human immune responses in humanized NSG mice, this strain has also been engineered to express HLA*A0201 covalently bound to human β2-microglobulin (NSG-HLA-A2/HHD mice) [105]. HLA-A2-restricted human T cell responses against both Epstein-Barr and dengue viruses have been detected in CD34[+] cell transplanted NSG-HLA-A2/HHD mice [83, 105]. This strain might offer an improved option for conducting human vaccine research in humanized mice. In short, the relatively poor human immune responses observed in CD34[+] cell transplanted DKO/NOG/NSG mice are leading to extensive and ongoing efforts to generate better human immune responses in these models.

HIV replication, pathogenesis and anti-viral responses

One observation is clear, virtually all types of HIV isolates tested to date replicate efficiently in humanized mice. They include: subtype B — R5-tropic [JRCSF, BaL, YU-2, ADA, NFN-SX(SL9), UG029A] [29, 61, 66, 89, 90, 120-132], X4-tropic [NL4-3, LAI, MNp] [29, 30,

61, 66, 91, 124, 128, 131-134], and dual-tropic [NL4-3RA, R3A] [131, 135]; subtype C — [C1157] [61]. In addition, one SHIV — [SHIV-C2/1] has also been shown to replicate in humanized mice [132]. HIV replication has been monitored in individual animals for over a year and mucosal HIV transmission typically results in the expected replication kinetics of peak viremia followed by viral set point levels in humanized mice [123, 124]. Intravenous and intraperitoneal HIV exposures were used in most of these studies, while vaginal or rectal viral exposures were used in six reports [90, 91, 113, 115, 123, 136]. Once infection occurs, HIV is systemically disseminated. Infection results in similar manifestations in all models, including CD4+ T cell loss and CD8+ T cell infiltration, regardless of the route of exposure [137]. Table 1 summarizes the humanized mouse model, the route of mucosal exposure and the type of experiment performed for each of the studies cited above. In all these studies, peripheral blood plus primary and secondary lymphoid tissues were most commonly examined. CXCR4-tropic HIV isolates in general showed the most dramatic pathogenic phenotypes and a single point mutation (V38E) in the gp41 region of a CXCR4-tropic HIV isolate was found to significantly alter the ability of the mutant virus to deplete CD4+ T cells [133, 137]. It should be noted that HIV pathology in humanized mouse intestines, including reduced gut effector memory CD4+ T cells as seen in human HIV infections, have only been described in BLT mice [90, 91, 138].

HIV-specific immune responses have been examined in infected humanized mice (Table1). However, HIV-specific humoral and cellular immune responses have only been consistently observed in BLT mice [89, 91]. In particular, interferon-gamma producing T cells specific for *gag*, *nef*, *pol* and *env*, plus HLA-restricted cytotoxic T lymphocytes specific for known *gag*- and *nef*-epitopes have been detected in BLT mice. All BLT mice evaluated (n=9) developed human antibody responses to HIV by 12 weeks post-exposure [89]. In addition to this work in BLT mice, CD34+ cell transplanted NOG, NSG and DKO mice have also been reported to generate HIV-specific human immune responses, although human HIV-specific humoral responses are much less frequent in these models [137]. More recently, the role of CD8+ T cells in HIV infected CD34+ cell transplanted NSG mice was investigated by Gorantla, *et al.* who showed that viral RNA levels in plasma are increased and CD4+ T cell loss is accelerated when human CD8+ T cells are specifically depleted [125]. This is similar to what has been observed in NHP [139, 140]. A pair of papers by Gorantla, *et al.* and Dash, *et al.* utilized CD34+ cell transplanted NSG mice to demonstrate multi-lineage human immune cells in the humanized mouse brain as well as significant neuropathology following HIV infection in these animals [121, 122]. Jiang, *et al.* demonstrated that FoxP3+CD4+ regulatory T cells are preferentially infected and depleted by HIV in CD34+ cell transplanted DKO mice and that depletion of the FoxP3+CD4+ regulatory T cells impaired HIV replication *in vivo* [135]. The role of immune activation in HIV infection in CD34+ cell transplanted DKO mice was examined by Hofer, *et al.* who found a positive association between chemically-induced bacterial translocation, higher viral loads and lower CD4+ T cell levels [126]. Additionally, Ince, *et al.* examined the evolution of CCR5-tropic HIV and found evidence for CD4+ T cell-induced selective pressure on HIV in CD34+ cell transplanted DKO mice [127]. In one animal, multiple clone sequences were obtained 44 weeks after infection. These sequences contained mutations that were functionally analyzed and determined to have an X4 phenotype indicating that a tropism switch had occurred in the humanized mouse [127]. Human anti-HIV innate immunity has also been examined in humanized mice. Specifically, Sato, *et al.* recently showed that human APOBEC3 proteins can induce mutations in the HIV genome in CD34+ cell transplanted NOG mice; however, there is a caveat to their interpretation that these mutations occurred despite a functional *vif* [129]. Specifically, the data presented indicates that in 3 out of 4 amplicons the *vif* sequence was found to be mutated, likely due to reverse transcriptase error, and this resulted in 3.5% of 86 *vif* amplicons being prematurely terminated. The 5 of 243 hypermutated (10+ G to A mutations) amplicons reported did not include *vif* sequence to confirm that *vif* was indeed

intact in the hypermutated viral DNA [129]. However, there is convincing evidence that cell-associated DNA carried more G to A mutations at canonical APOBEC 3G, 3F, or 3B sites when compared to circulating virions [129]. Overall, both innate and adaptive human immune responses occur in humanized mice and these responses can result in viral evolution.

HIV therapy

Preclinical evaluation of novel treatments has been an important application of humanized mice in HIV research. *In vivo* efficacy reports have focused on antiretroviral (ART) and gene therapies. Both established and investigational antiretrovirals have been tested in CD34+ cell transplanted humanized mice. Van Duyne, *et al.* have described *tat*-derived peptides reducing plasma viral RNA at a single time point in CD34+ cell transplanted DKO and NSG mice [141]. While this data is promising regarding the ability of the *tat*-derived peptides to reduce detectable plasma levels of HIV in these mice at two weeks post intraperitoneal inoculation, longitudinal peripheral blood analysis during ongoing treatment would further clarify the potential of these peptides for future clinical applications and provide information regarding the likelihood of developing resistance mutations *in vivo*.

ART has brought many benefits to HIV patients and demonstration of successful ART in humanized mice is critical to the future usefulness of these models. Choudhary, *et al.* determined peripheral blood and intestinal tissue levels of intraperitoneally delivered emtricitabine, tenofovir and the integrase inhibitor L-870812. This comprehensive pharmacokinetic analysis was used to develop a triple-combination ART dosing regimen in CD34+ cell transplanted DKO mice [114]. Longitudinal analysis of the effects of this antiretroviral combination showed reduced plasma viral RNA in HIV infected humanized mice [114]. In two mice, failure of therapy occurred due to the development of resistance mutations to tenofovir and to the integrase inhibitor suggesting that further optimization of this drug regimen is needed. Nevertheless, when ART was discontinued, the plasma viral RNA concentrations rebounded to pretreatment levels in all humanized mice tested [114]. Sango, *et al.* reported that ART consisting of AZT, lamivudine and indinavir suppressed HIV in CD34+ cell transplanted DKO mice [142]. This 7-week ART regimen, administered in sterile drinking water, was able to reduce recoverable replication competent virus from spleen (which is the site of virus inoculation) 300-fold compared to untreated control mice. HIV suppression *in vivo* typically refers to a durable reduction in plasma viremia to below the limit of detection; unfortunately, in this study only a single data point was reported for pooled (n=4) plasma RNA at the end of the 7-week ART regimen [142]. Analysis of pooled plasma can facilitate more sensitive viral RNA detection and 69 copies per ml was reported for the treated group, indicating that a relatively sensitive assay was used. No breakthrough in plasma viremia during ART was observed, although longitudinal data was not shown [142]. This research group also evaluated the ability of the broadly neutralizing anti-HIV antibody 2G12 to reduce HIV infection when expressed in humanized mice [143]. Human CD34+ cells were transduced with a lentiviral vector encoding 2G12 prior to being transplanted to generate humanized NSG mice. One week post-intraperitoneal HIV inoculation, mice were harvested and both the number of replication competent viruses recovered from the spleen and the number of plasma viral RNA copies were quantitated. The results showed that 2G12 reduced recoverable virus 200-fold and the pooled plasma showed a 70-fold reduction in viral RNA copies versus control [143]. When a separate research group utilized dimeric 2G12 sustained at low levels in peripheral blood via "back pack" administration units on CD34+ cell transplanted DKO mice, they found that this dimerized neutralizing antibody further reduced the detectable viral load and lessened the loss of CD4+ T cell associated with HIV infection when compared to treatment with monomeric 2G12 [144]. The data presented from these manuscripts demonstrates successful

therapy in humanized mice helping to fulfill the critical need for the validation of humanized mice for preclinical evaluation of novel therapeutic interventions.

HIV infection requires the presence of both a primary receptor (CD4) and a co-receptor (CCR5/CXCR4). Several therapeutic strategies targeting CD4 or CCR5 have been considered. There is great potential for the curative capacity of such approaches as illustrated first by the effective clinical use of CCR5 targeted therapies and by the long-term control of HIV infection in an HIV-positive patient with acute myeloid leukemia [145]. This patient received two hematopoietic stem cell transplants from the same HLA-matched transplant donor who was homozygous for a 32 base pair deletion in CCR5 (delta 32). CCR5 containing this delta 32 deletion is no longer is capable of acting as a co-receptor for HIV [146]. Therefore, the CCR5$^{\Delta 32/\Delta 32}$ cells derived from the donor stem cells are resistant to HIV infection and the transplant recipient's viral load has remained undetectable for more than 3.5 years in the absence of ART [145, 147]. Holt, *et al.* tested an exciting application of therapeutically mutating CCR5 in the human cells of CD34$^+$ cell transplanted NSG mice. They evaluated the ability of CCR5-targeting zinc-finger nucleases to control HIV infection [148]. CD34$^+$ cells were nucleofected with zinc-finger nuclease expression plasmids prior to transplantation. The human hematopoietic cells in the mice transplanted with nucleofected cells had disrupted CCR5 expression. An advantage of the zinc-finger nuclease approach is this disruption of the CCR5 gene is permanent, thus all progeny of altered CD34$^+$ cells are unable to express CCR5 with no overt functional defects. The CCR5-deficient CD4$^+$ T cells (estimated at 5-7% of the original total CD4$^+$ T cell population) survived HIV mediated cytopathology and expanded to pre-infection levels [148].

Novel strategies for targeted delivery of siRNA as HIV therapy have also been evaluated in humanized mice [149]. Kumar, *et al.* developed and tested a CD7-specific targeting construct that can deliver anti-CD4, -CCR5, -vif and -tat siRNAs specifically to human T cells. These constructs were shown to reduce surface CD4 expression on activated PBMC by 1 log [150]. CD34$^+$ cell transplanted NSG mice were treated intravenously with an anti-vif/tat construct and then infected intraperitoneally with HIV 18 hours later. Subsequent administrations of the construct followed at 4-5 day intervals for a total of 40 days. Despite the fact that this approach did not prevent infection, the peak plasma viral loads in the treated mice was 30-fold lower in treated mice when compared to the control siRNA-construct treated mice. This reduction in viral levels was maintained for the duration of the experiment [150]. Kim, *et al.* utilized BLT mice to examine whether RNAi-mediated silencing of CCR5 expression could prevent infection after intraperitoneal injection of HIV [151]. Their novel immunoliposome siRNA delivery method specifically targeted lymphocytes for RNA interference based on lymphocyte function-associated antigen-1 (LFA-1) expression. Targeted administration of the siRNA resulted in a reduction in plasma viral RNA levels and CD4$^+$ T cell loss, but did not prevent infection from occurring [151]. Neff, *et al.* have shown that aptamer delivered siRNA targeting HIV tat and rev suppressed plasma viral load levels by several orders of magnitude in CD34$^+$ cell transplanted DKO mice [134]. In four treated animals, weekly treatment with the Ch A-1 aptamer was sufficient to suppress viral load to levels below detection for up to 3 weeks after treatment was ceased; however, viral breakthrough did occur in two mice after 3 weeks of treatment suggestive of the development of resistance to Ch A-1 [134]. None of these siRNA-based methods permanently alter the genomic DNA, as with the zinc-finger nuclease above. Still they hold great promise as HIV therapeutics precisely because they do not require *ex vivo* manipulation of targeted cells.

Mucosal HIV transmission

Unprotected intercourse accounts for the majority of new HIV transmissions [1]. Reliable mucosal HIV transmission in humanized mouse models, like that observed for the BLT

model, has opened new opportunities for *in vivo* evaluation of prevention strategies. Vaginal and rectal HIV infection in humanized mice is contingent on the presence of the human cells necessary for transmission in the female reproductive tract and the rectum. However, it is the chosen mouse strain and humanization protocol that determines the extent of human reconstitution in these important tissues. As described above, human CD4[+] T cells, monocyte/macrophages and dendritic cells extensively reconstitute all regions of the BLT mouse female reproductive tract [90, 137, 152]. The extensive reconstitution of these mucosal sites in BLT mice renders these animals susceptible to efficient vaginal HIV transmission (7 of 8 total [R5]) [90, 153]. Furthermore, the reconstitution of the intestines, including the rectum of BLT mice with human cells required for HIV transmission renders them also susceptible to rectal HIV transmission (18 of 26 total [X4 and R5]) [91, 136].

The mucosal transmission of HIV in CD34[+] cell transplanted NOG/NSG mice has not been addressed in the literature. However, mucosal transmission has been examined in CD34[+] cell transplanted DKO mice. Particularly in the case of rectal exposure in this model, there is a discrepancy in the literature regarding their susceptibility to HIV transmission. Among the four research groups that have examined the human reconstitution of these mucosal tissues described above [77, 113-115], only two groups have attempted either vaginal or rectal HIV transmission in these mice. Vaginal HIV transmission has been shown to be efficient in this model twice by the same group (20 of 21 total [X4 and R5]) [113, 123]. However, when both groups attempted rectal HIV transmission in CD34[+] cell transplanted DKO mice, the results were entirely different [30, 115]. In one case transmission was efficient (11 of 14 total [X4 and R5]), while rectal transmission was rare in the other report regardless of whether inoculation occurred with cell-free or cell-associated HIV (1 of 23 total [R5]) [30, 115]. In this second report, the authors also unsuccessfully attempted to increase rectal HIV transmission in these mice by rectal administration of IL-1beta 24 hours preceding viral exposure in the presence or in the absence of human seminal plasma (1 of 17 total [R5]) [115]. Additional work must be done to address this dramatic discrepancy in the susceptibility of CD34[+] cell transplanted DKO mice to rectal HIV transmission.

HIV prevention

HIV continues to spread at an alarming rate and successful biomedical HIV prevention tools are urgently needed. Mucosal HIV transmission accounts for the vast majority of new HIV infections. The fact that vaginal and rectal HIV transmission can be reproducibly performed in BLT mice makes this model, along with the CD34[+] cell transplanted DKO mice, a critical component in our response to this pandemic in that they will serve as outstanding models for the preclinical evaluation of HIV prevention strategies.

Clinical interventions designed to decrease HIV transmission currently being tested include topical pre-exposure prophylaxis (PrEP) and systemic PrEP with antiretrovirals. Recently, the CAPRISA 004 clinical trial reported that 1% tenofovir applied vaginally before and after intercourse resulted in a 39% reduction in incidence of HIV in the two high risk populations of South African women enrolled[154]. Subsequently, the iPrEx clinical trial reported that daily oral emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) (co-formulated as Truvada®) led to a 44% reduction in incidence in HIV in men who have sex with men at eleven sites in 6 countries [155]. When adjustments were made to account for adherence in the iPrEx trial participants as defined by detectable study drugs in plasma, the reduction in incidence was 92%. These very encouraging data show that antiretroviral PrEP has the potential to slow the spread of HIV in high-risk populations. These observations also bring us to a critical line of investigation in humanized mice: preclinical *in vivo* efficacy evaluations of biomedical interventions for HIV prevention such as topical and systemic PrEP.

To date, there are no reports published regarding the efficacy evaluation of topical PrEP (microbicides) for the prevention of HIV in humanized mice, but both BLT mice and CD34[+] cell transplanted DKO mice have been used to demonstrate *in vivo* the efficacy of systemic PrEP in preventing HIV transmission [90, 123, 136]. BLT mice were treated once daily for seven days with Truvada, in a manner that recapitulated the experimental design used for the iPrEx trial [155]. Three hours following the third FTC/TDF dose, mice were rectally exposed to HIV. FTC and TDF were very effective at protecting BLT mice from rectal HIV transmission with a protection level of 100% [136]. The iPrEx trial results indicated that the most adherent participants experienced a greater than 90% reduction in incidence and the BLT mouse result that 100% of mice were protected together show that daily systemic FTC/TDF can prevent rectal HIV transmission and the similar protection levels observed in both studies serves to validate the BLT system for further preclinical efficacy evaluations of novel HIV prevention approaches. To this end, the same 7-day regimen of FTC/TDF used for the rectal study also prevented 100% of vaginal transmissions in BLT mice [90]. Therefore, given the success of systemic PrEP in humans and BLT mice for the prevention of rectal HIV transmission, as well as for the prevention of vaginal HIV transmission in BLT mice, there is reason to be optimistic regarding the outcomes of ongoing clinical trials evaluating systemic PrEP with FTC/TDF to prevent vaginal transmission in women. In the case of intravenous exposure, the seven day PrEP regimen resulted in 88% protection from transmission in BLT mice [136]. However, when the FTC/TDF treatment was begun 24 hours following intravenous HIV inoculation, detection of the virus in plasma was only delayed. This post exposure prophylactic approach offered 0% protection from intravenous HIV transmission [136]. Consequently, having the drugs present systemically prior to exposure was important for the protection of BLT mice from intravenous HIV transmission. The drug investigation pipeline in humanized mice was expanded by Neff, *et al.* who tested closely related 7-day systemic PrEP regimens consisting of either oral raltegravir (an integrase inhibitor) or oral maraviroc (a CCR5 inhibitor) [123]. They found that each drug showed 100% efficacy at preventing vaginal HIV transmission in these CD34[+] cell transplanted DKO mice [123]. In conclusion, the iPrEx trial results validate the BLT model for the preclinical efficacy evaluation of biomedical interventions to prevent rectal HIV transmission which highlights the usefulness of the model for the preclinical efficacy screening of other prevention interventions, including microbicides.

Conclusions and Future Directions

The versatility of humanized mice in HIV research is evident in the body of work presented here. The ability to study HIV biology and anti-HIV approaches *in vivo* using humanized mice is a major advance in the field of HIV research. These mouse models are already being utilized to perform preclinical efficacy evaluations of HIV prevention and HIV therapeutic interventions, but they can be used to a much greater extent in these efforts. To best harness the power of the humanized mouse models we need to know more about the human immune responses occurring in these animals. It will be critical to discern whether anti-HIV NK responses are occurring as well as whether HIV neutralizing antibody titers (broad or narrow) are being generated within humanized mice, what is the magnitude of any detected responses and whether secretory IgA or other antibody isotypes are involved in the response. An underexplored area of humanized mouse research is their potential usefulness for vaccines. Functional human anti-viral immune responses in BLT mice combined with relevant routes of infection provide a unique opportunity to evaluate protective HIV-specific immune responses. Furthermore, the ability to reliably perform mucosal HIV transmissions, especially in BLT mice, presents numerous opportunities for examining the protective effects of antibodies at mucosal surfaces. Another critical experimental question to address in HIV infected humanized mice is: does the development and maintenance of a latent viral reservoir during anti-retroviral therapy occur in humanized mice as it does in humans?

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Focusing research in humanized mice on each of these critical aspects of the fight against HIV can accelerate the effort to help individuals infected with HIV or at risk of becoming infected with HIV. This effort will be further enhanced as humanized mouse researchers begin to diligently compare data from their humanized mouse research with data available from human and NHP studies whenever possible. In the future we expect significant refinements to these humanized mouse systems, which will enhance the already enormous potential of humanized mice to contribute to all aspects of HIV researchss.

Acknowledgments

References

1. WHO-UNAIDS. 2010 Report on the Global AIDS Epidemic. UNAIDS; Geneva, Switzerland: 2010.

2. Abner SR, Guenthner PC, Guarner J, et al. A Human Colorectal Explant Culture to Evaluate Topical Microbicides for the Prevention of HIV Infection. J Infect Dis. 2005; 192(9):1545–1556. [PubMed: 16206069]

3. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007; 26(2):257–270. [PubMed: 17306567]

4. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE. 2010; 5(2):e9310. [PubMed: 20174579]

5. Wei BL, Denton PW, O'Neill E, et al. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol. 2005; 79(9):5705–5712. [PubMed: 15827185]

6. Hatziioannou T, Ambrose Z, Chung NP, et al. A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A. 2009; 106(11):4425–4429. [PubMed: 19255423]

7. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science. 2006; 313(5786):523–526. [PubMed: 16728595]

8. Neel C, Etienne L, Li Y, et al. Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas. J Virol. 2010; 84(3):1464–1476. [PubMed: 19906908]

9. Keele BF, Jones JH, Terio KA, et al. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature. 2009; 460(7254):515–519. [PubMed: 19626114]

10. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008; 5(2):e28. [PubMed: 18254653]

11. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol. 2009; 83(20):10358–10365. [PubMed: 19656878]

12. Veazey RS. Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr Opin HIV AIDS. 2008; 3(5):567–573. [PubMed: 19373023]

13. Veazey RS, Springer MS, Marx PA, et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med. 2005; 11(12):1293–1294. [PubMed: 16273102]

14. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008; 14(6):617–621. [PubMed: 18535579]

15. Zink MC, Laast VA, Helke KL, et al. From mice to macaques--animal models of HIV nervous system disease. Curr HIV Res. 2006; 4(3):293–305. [PubMed: 16842082]

16. Behringer RR. Human-animal chimeras in biomedical research. Cell Stem Cell. 2007; 1(3):259–262. [PubMed: 18371360]

17. Bernard D, Peakman M, Hayday AC. Establishing humanized mice using stem cells: maximizing the potential. Clin Exp Immunol. 2008; 152(3):406–414. [PubMed: 18435804]

18. Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes. 2010; 17(2):120–125. [PubMed: 20150806]

19. Goldstein H. Summary of presentations at the NIH/NIAID New Humanized Rodent Models 2007 Workshop. AIDS Res Ther. 2008; 5:3. [PubMed: 18237418]

20. Manz MG, Di Santo JP. Renaissance for mouse models of human hematopoiesis and immunobiology. Nat Immunol. 2009; 10(10):1039–1042. [PubMed: 19767720]

21. Van Duyne R, Pedati C, Guendel I, et al. The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology. 2009; 6:76. [PubMed: 19674458]

22. Zhang L, Meissner E, Chen J, Su L. Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis. Sci China Life Sci. 2010; 53(2):195–203. [PubMed: 20596827]

23. Hiramatsu H, Nishikomori R, Heike T, et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood. 2003; 102(3):873–880. [PubMed: 12689924]

24. Manz MG. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity. 2007; 26(5):537–541. [PubMed: 17521579]

25. Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005; 106:1565–1573. [PubMed: 15920010]

26. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004; 304(5667):104–107. [PubMed: 15064419]

27. Lan P, Tonomura N, Shimizu A, Wang S, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood. 2006; 108(2):487–492. [PubMed: 16410443]

28. Melkus MW, Estes JD, Padgett-Thomas A, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med. 2006; 12(11):1316–1322. [PubMed: 17057712]

29. Baenziger S, Tussiwand R, Schlaepfer E, et al. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci U S A. 2006; 103(43):15951–15956. [PubMed: 17038503]

30. Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology. 2006; 3:76. [PubMed: 17078891]

31. Zhang JX, Diehl GE, Littman DR. Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PLoS ONE. 2008; 3(4):e2035. [PubMed: 18446227]

32. Boberg A, Brave A, Johansson S, et al. Murine models for HIV vaccination and challenge. Expert Rev Vaccines. 2008; 7(1):117–130. [PubMed: 18251698]

33. Bieniasz PD, Cullen BR. Multiple Blocks to Human Immunodeficiency Virus Type 1 Replication in Rodent Cells. J Virol. 2000; 74(21):9868–9877. [PubMed: 11024113]

34. Mariani R, Rutter G, Harris ME, et al. A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol. 2000; 74(8):3859–3870. [PubMed: 10729160]

35. McCune JM, Namikawa R, Kaneshima H, et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science. 1988; 241(4873):1632–1639. [PubMed: 2971269]

36. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 1988; 335(6187):256–259. [PubMed: 2970594]

37. Aldrovandi GM, Feuer G, Gao L, et al. The SCID-hu mouse as a model for HIV-1 infection. Nature. 1993; 363(6431):732–736. [PubMed: 8515816]

38. Delhem N, Hadida F, Gorochov G, et al. Primary Th1 cell immunization against HIVgp160 in SCID-hu mice coengrafted with peripheral blood lymphocytes and skin. J Immunol. 1998; 161(4): 2060–2069. [PubMed: 9712080]

39. Banerjea A, Li M, Bauer G, et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther. 2003; 8(1):62–71. [PubMed: 12842429]

40. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA. Generation of HIV latency during thymopoiesis. Nat Med. 2001; 7(4):459–464. [PubMed: 11283673]

41. Rabin L, Hincenbergs M, Moreno MB, et al. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob Agents Chemother. 1996; 40(3):755–762. [PubMed: 8851606]

42. Stoddart CA, Bales CA, Bare JC, et al. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS ONE. 2007; 2(7):e655. [PubMed: 17668043]

43. D'Cruz OJ, Uckun FM. Limitations of the human-PBL-SCID mouse model for vaginal transmission of HIV-1. Am J Reprod Immunol. 2007; 57(5):353–360. [PubMed: 17430499]

44. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007; 7(2):118–130. [PubMed: 17259968]

45. Greiner DL, Shultz LD, Yates J, et al. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am J Pathol. 1995; 146(4):888–902. [PubMed: 7717456]

46. Ueda T, Yoshino H, Kobayashi K, et al. Hematopoietic repopulating ability of cord blood CD34(+) cells in NOD/Shi-scid mice. Stem Cells. 2000; 18(3):204–213. [PubMed: 10840074]

47. Mazurier F, Fontanellas A, Salesse S, et al. A novel immunodeficient mouse model--RAG2 × common cytokine receptor gamma chain double mutants--requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. J Interferon Cytokine Res. 1999; 19(5):533–541. [PubMed: 10386866]

48. Huntington ND, Legrand N, Alves NL, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med. 2009; 206(1):25–34. [PubMed: 19103877]

49. Legrand N, Weijer K, Spits H. Experimental model for the study of the human immune system: production and monitoring of "human immune system" Rag2-/-gamma c-/- mice. Methods Mol Biol. 2008; 415:65–82. [PubMed: 18370148]

50. Cao X, Shores EW, Hu-Li J, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity. 1995; 2(3):223–238. [PubMed: 7697543]

51. Ohbo K, Suda T, Hashiyama M, et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood. 1996; 87(3):956–967. [PubMed: 8562967]

52. Yu CI, Gallegos M, Marches F, et al. Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood. 2008; 112(9):3671–3678. [PubMed: 18713944]

53. Pearson T, Shultz LD, Miller D, et al. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol. 2008; 154(2):270–284. [PubMed: 18785974]

54. Pedroza-Gonzalez A, Xu K, Wu TC, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. The Journal of Experimental Medicine. 2011

55. McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. 2010; 116(2):193–200. [PubMed: 20404133]

56. Martin-Padura I, Agliano A, Marighetti P, Porretti L, Bertolini F. Sex-related efficiency in NSG mouse engraftment. Blood. 2010; 116(14):2616–2617. [PubMed: 20930083]

57. Notta F, Doulatov S, Dick JE. Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients. Blood. 2010; 115(18):3704–3707. [PubMed: 20207983]

58. Choi B, Chun E, Kim M, et al. Human B Cell Development and Antibody Production in Humanized NOD/SCID/IL-2Rgamma(null) (NSG) Mice Conditioned by Busulfan. J Clin Immunol. 2010 In Press.

59. Brehm MA, Cuthbert A, Yang C, et al. Parameters for establishing humanized mouse models to study human immunity: Analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol. 2010; 135(1):84–98. [PubMed: 20096637]

60. Lepus CM, Gibson TF, Gerber SA, et al. Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol. 2009; 70(10):790–802. [PubMed: 19524633]

61. Gorantla S, Sneller H, Walters L, et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol. 2007; 81(6):2700–2712. [PubMed: 17182671]

62. Hayakawa J, Hsieh MM, Uchida N, Phang O, Tisdale JF. Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice. Stem Cells. 2009; 27(1):175–182. [PubMed: 18927475]

63. Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10):6477–6489. [PubMed: 15879151]

64. Nauta AJ, Kruisselbrink AB, Lurvink E, et al. Enhanced engraftment of umbilical cord blood-derived stem cells in NOD/SCID mice by cotransplantation of a second unrelated cord blood unit. Exp Hematol. 2005; 33(10):1249–1256. [PubMed: 16219548]

65. Kim DW, Chung YJ, Kim TG, Kim YL, Oh IH. Co-transplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Blood. 2004; 103(5):1941–1948. [PubMed: 14592834]

66. Watanabe S, Ohta S, Yajima M, et al. Humanized NOD/SCID/IL2R {gamma}null Mice Transplanted with Hematopoietic Stem Cells under Nonmyeloablative Conditions Show Prolonged Life Spans and Allow Detailed Analysis of Human Immunodeficiency Virus Type 1 Pathogenesis. J Virol. 2007; 81(23):13259–13264. [PubMed: 17881441]

67. King M, Pearson T, Rossini AA, Shultz LD, Greiner DL. Humanized mice for the study of type 1 diabetes and beta cell function. Ann N Y Acad Sci. 2008; 1150:46–53. [PubMed: 19120266]

68. Chang NH, Inman RD, Dick JE, Wither JE. Bone marrow-derived human hematopoietic stem cells engraft NOD/SCID mice and traffic appropriately to an inflammatory stimulus in the joint. J Rheumatol. 2010; 37(3):496–502. [PubMed: 20110518]

69. Kwant-Mitchell A, Pek EA, Rosenthal KL, Ashkar AA. Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge. PLoS ONE. 2009; 4(12):e8379. [PubMed: 20027308]

70. Sellier-Leclerc AL, Duval A, Riveron S, et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol. 2007; 18(10):2732–2739. [PubMed: 17855645]

71. Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, et al. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol. 2004; 78(24):13891–13900. [PubMed: 15564497]

72. Ma SD, Hegde S, Young KH, et al. A new model of EBV infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol. 2010; 85(1):165–177. [PubMed: 20980506]

73. Strowig T, Gurer C, Ploss A, et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med. 2009; 206(6):1423–1434. [PubMed: 19487422]

74. Yajima M, Imadome K, Nakagawa A, et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis. 2008; 198(5):673–682. [PubMed: 18627269]

75. Washburn ML, Bility MT, Zhang L, et al. A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease. Gastroenterology. 2011 In Press.

76. Smith MS, Goldman DC, Bailey AS, et al. Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe. 2010; 8(3):284–291. [PubMed: 20833379]

77. Kwant-Mitchell A, Ashkar AA, Rosenthal KL. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J Virol. 2009; 83(20):10664–10676. [PubMed: 19656896]

78. Libby SJ, Brehm MA, Greiner DL, et al. Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci U S A. 2010; 107(35): 15589–15594. [PubMed: 20713716]

79. Song J, Willinger T, Rongvaux A, et al. A mouse model for the human pathogen Salmonella typhi. Cell Host Microbe. 2010; 8(4):369–376. [PubMed: 20951970]

80. Firoz Mian M, Pek EA, Chenoweth MJ, Ashkar AA. Humanized mice are susceptible to Salmonella typhi infection. Cell Mol Immunol. 2011; 8(1):83–87. [PubMed: 21200387]

81. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J Leukoc Biol. 2009; 86(2): 219–227. [PubMed: 19369639]

82. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J Virol. 2005; 79(21):13797–13799. [PubMed: 16227299]

83. Jaiswal S, Pearson T, Friberg H, et al. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS ONE. 2009; 4(10):e7251. [PubMed: 19802382]

84. Kuruvilla JG, Troyer RM, Devi S, Akkina R. Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice. Virology. 2007; 369(1):143–152. [PubMed: 17707071]

85. Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol. 2009; 83(17):8638–8645. [PubMed: 19535452]

86. Subramanya S, Kim SS, Abraham S, et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol. 2010; 84(5):2490–2501. [PubMed: 20015996]

87. Vasilakis N, Cardosa J, Diallo M, et al. Sylvatic dengue viruses share the pathogenic potential of urban/endemic dengue viruses. J Virol. 2010; 84(7):3726–3727. author reply 3727-3728. [PubMed: 20212326]

88. Centlivre M, Zhou X, Pouw SM, et al. Autoregulatory lentiviral vectors allow multiple cycles of doxycycline-inducible gene expression in human hematopoietic cells in vivo. Gene Ther. 2010; 17(1):14–25. [PubMed: 19727135]

89. Brainard DM, Seung E, Frahm N, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol. 2009; 83(14):7305–7321. [PubMed: 19420076]

90. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008; 5(1):e16. [PubMed: 18198941]

91. Sun Z, Denton PW, Estes JD, et al. Intrarectal transmission, systemic infection and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med. 2007; 204:705–714. [PubMed: 17389241]

92. Shimizu S, Hong P, Arumugam B, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood. 2010; 115(8):1534–1544. [PubMed: 20018916]

93. Rajesh D, Zhou Y, Jankowska-Gan E, et al. Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice. Hum Immunol. 2010; 71(6):551–559. [PubMed: 20298731]

94. Tonomura N, Habiro K, Shimizu A, Sykes M, Yang YG. Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood. 2008; 111(8):4293–4296. [PubMed: 18270327]

95. Tonomura N, Shimizu A, Wang S, et al. Pig islet xenograft rejection in a mouse model with an established human immune system. Xenotransplantation. 2008; 15(2):129–135. [PubMed: 18447886]

96. Abuzakouk M, Carton J, Feighery C, et al. CD4+ CD8+ and CD8alpha+ beta- T lymphocytes in human small intestinal lamina propria. Eur J Gastroenterol Hepatol. 1998; 10(4):325–329. [PubMed: 9855049]

97. Carton J, Byrne B, Madrigal-Estebas L, O'Donoghue DP, O'Farrelly C. CD4+CD8+ human small intestinal T cells are decreased in coeliac patients, with CD8 expression downregulated on intra-epithelial T cells in the active disease. Eur J Gastroenterol Hepatol. 2004; 16(10):961–968. [PubMed: 15371918]

98. Bird P, Calvert JE, Amlot PL. Distinctive development of IgG4 subclass antibodies in the primary and secondary responses to keyhole limpet haemocyanin in man. Immunology. 1990; 69(3):355–360. [PubMed: 2312160]

99. Becker PD, Legrand N, van Geelen CM, et al. Generation of Human Antigen-Specific Monoclonal IgM Antibodies Using Vaccinated "Human Immune System" Mice. PLoS ONE. 2010; 5(10):e13137. [PubMed: 20957227]

100. Ter Brake O, Legrand N, von Eije KJ, et al. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)(c)(-/-)) mouse model. Gene Ther. 2008; 16(1): 148–153. [PubMed: 18668146]

101. Gimeno R, Weijer K, Voordouw A, et al. Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells. Blood. 2004; 104(13):3886–3893. [PubMed: 15319293]

102. Coles MC, Veiga-Fernandes H, Foster KE, et al. Role of T and NK cells and IL7/IL7r interactions during neonatal maturation of lymph nodes. Proc Natl Acad Sci U S A. 2006; 103(36):13457–13462. [PubMed: 16938836]

103. Pek EA, Chan T, Reid S, Ashkar AA. Characterization and IL-15 dependence of NK cells in humanized mice. Immunobiology. 2010; 216(1-2):218–224. [PubMed: 20627447]

104. Scheeren FA, Nagasawa M, Weijer K, et al. T cell-independent development and induction of somatic hypermutation in human IgM+ IgD+ CD27+ B cells. J Exp Med. 2008; 205(9):2033–2042. [PubMed: 18695003]

105. Shultz LD, Saito Y, Najima Y, et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A. 2010; 107(29):13022–13027. [PubMed: 20615947]

106. van Lent AU, Dontje W, Nagasawa M, et al. IL-7 enhances thymic human T cell development in "human immune system" Rag2-/-IL-2Rgammac-/- mice without affecting peripheral T cell homeostasis. J Immunol. 2009; 183(12):7645–7655. [PubMed: 19923447]

107. Zhang J, Chen Z, Smith GN, Croy BA. Natural killer cell-triggered vascular transformation: maternal care before birth? Cell Mol Immunol. 2010; 8(1):1–11. [PubMed: 20711229]

108. Kiem HP, Wu RA, Sun G, et al. Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther. 2010; 17(1):37–49. [PubMed: 19741733]

109. Chen Q, Khoury M, Chen J. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A. 2009; 106(51):21783–21788. [PubMed: 19966223]

110. Eldjerou LK, Chaudhury S, Baisre-de Leon A, et al. An in vivo model of double unit cord blood transplantation that correlates with clinical engraftment. Blood. 2010; 116(19):3999–4006. [PubMed: 20587781]

111. Watanabe Y, Takahashi T, Okajima A, et al. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol. 2009; 21(7):843–858. [PubMed: 19515798]

112. Yahata T, Ando K, Nakamura Y, et al. Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor gamma null mice. J Immunol. 2002; 169(1):204–209. [PubMed: 12077246]

113. Berges BK, Akkina SR, Folkvord JM, Connick E, Akkina R. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice. Virology. 2008; 373(2):342–351. [PubMed: 18207484]

114. Choudhary SK, Rezk NL, Ince WL, et al. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/-mouse. J Virol. 2009; 83(16):8254–8258. [PubMed: 19494021]

115. Hofer U, Baenziger S, Heikenwalder M, et al. RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus. J Virol. 2008; 82(24):12145–12153. [PubMed: 18842716]

116. Andre MC, Erbacher A, Gille C, et al. Long-term human CD34(+) stem cell-engrafted nonobese diabetic/SCID/IL-2Rgamma(null) mice show impaired CD8(+) T cell maintenance and a functional arrest of immature NK cells. J Immunol. 2010; 185(5):2710–2720. [PubMed: 20668220]

117. Sato Y, Takata H, Kobayashi N, et al. Failure of effector function of human CD8+ T Cells in NOD/SCID/JAK3/immunodeficient mice transplanted with human CD34+ hematopoietic stem cells. PLoS ONE. 2010; 5(10):e13109. [PubMed: 20957041]

118. Rongvaux A, Willinger T, Takizawa H, et al. Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proc Natl Acad Sci U S A. 2011; 108(6):2378–2383. [PubMed: 21262827]

119. Billerbeck E, Barry WT, Mu K, et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor, GM-CSF and interleukin 3 expressing NOD SCID IL2R{gamma}NULL humanized mice. Blood. 2011 In Press.

120. An DS, Poon B, Ho Tsong Fang R, et al. Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol. 2007; 14(4):391–396. [PubMed: 17314230]

121. Gorantla S, Makarov E, Finke-Dwyer J, et al. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol. 2010; 177(6):2938–2949. [PubMed: 21088215]

122. Dash PK, Gorantla S, Gendelman HE, et al. Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice. J Neurosci. 2011; 31(9):3148–3157. [PubMed: 21368026]

123. Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS ONE. 2010; 5(12):e15257. [PubMed: 21203568]

124. Berges BK, Akkina SR, Remling L, Akkina R. Humanized Rag2(-/-) gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology. 2009; 397(1):100–103. [PubMed: 19922970]

125. Gorantla S, Makarov E, Finke-Dwyer J, et al. CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol. 2010; 184(12):7082–7091. [PubMed: 20495069]

126. Hofer U, Schlaepfer E, Baenziger S, et al. Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathog. 2010; 6(4):e1000867. [PubMed: 20442871]

127. Ince WL, Zhang L, Jiang Q, et al. Evolution of the HIV-1 env Gene in the Rag2-/-{gamma}C-/- Humanized Mouse Model. J Virol. 2009; 84(6):2740–2752. [PubMed: 20042504]

128. Nie C, Sato K, Misawa N, et al. Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice. Virology. 2009; 394(1):64–72. [PubMed: 19744686]

129. Sato K, Izumi T, Misawa N, et al. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol. 2010; 84(18):9546–9556. [PubMed: 20610708]

130. Sato K, Nie C, Misawa N, et al. Dynamics of memory and naive CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1. Vaccine. 2010; 28(2):B32–37. [PubMed: 20510741]

131. Zhang L, Kovalev GI, Su L. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood. 2007; 109(7):2978–2981. [PubMed: 17132723]

132. Watanabe S, Terashima K, Ohta S, et al. Hematopoietic stem cell-engrafted NOD/SCID/ IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood. 2007; 109(1):212–218. [PubMed: 16954502]

133. Garg H, Joshi A, Ye C, Shankar P, Manjunath N. Single amino acid change in gp41 region of HIV-1 alters bystander apoptosis and CD4 decline in humanized mice. Virol J. 2011; 8(1):34. [PubMed: 21255440]

134. Neff CP, Zhou J, Remling L, et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med. 2011; 3(66): 66ra66.

135. Jiang Q, Zhang L, Wang R, et al. FoxP3+CD4+ Treg cells play an important role in acute HIV-1 infection in humanized rag2-/-{gamma}C-/- mice in vivo. Blood. 2008; 112(7):2858–2868. [PubMed: 18544681]

136. Denton PW, Krisko JF, Powell DA, et al. Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice. PLoS ONE. 2010; 5(1):e8829. [PubMed: 20098623]

137. Denton PW, Garcia JV. Novel humanized murine models for HIV research. Curr HIV/AIDS Rep. 2009; 6(1):13–19. [PubMed: 19149992]

138. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004; 200(6):749–759. [PubMed: 15365096]

139. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999; 189(6):991–998. [PubMed: 10075982]

140. Matano T, Shibata R, Siemon C, et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol. 1998; 72(1):164–169. [PubMed: 9420212]

141. Van Duyne R, Cardenas J, Easley R, et al. Effect of transcription peptide inhibitors on HIV-1 replication. Virology. 2008; 376(2):308–322. [PubMed: 18455747]

142. Sango K, Joseph A, Patel M, et al. Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice. AIDS Res Hum Retroviruses. 2010; 26(7):735–746. [PubMed: 20624075]

143. Joseph A, Zheng JH, Chen K, et al. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol. 2010; 84(13):6645–6653. [PubMed: 20410262]

144. Luo XM, Lei MY, Feidi RA, et al. Dimeric 2G12 as a potent protection against HIV-1. PLoS Pathog. 2010; 6(12):e1001225. [PubMed: 21187894]

145. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692–698. [PubMed: 19213682]

146. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996; 2(11):1240–1243. [PubMed: 8898752]

147. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5{Delta}32/ {Delta}32 stem cell transplantation. Blood. 2010 In Press.

148. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010; 28(8):839–847. [PubMed: 20601939]

149. Subramanya S, Kim SS, Manjunath N, Shankar P. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther. 2010; 10(2):201–213. [PubMed: 20088715]

150. Kumar P, Ban HS, Kim SS, et al. T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice. Cell. 2008; 134(4):577–586. [PubMed: 18691745]

151. Kim SS, Peer D, Kumar P, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther. 2010; 18(2):370–376. [PubMed: 19997090]

152. Olesen R, Wahl A, Denton PW, Victor Garcia J. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol. 2011 In Press.

153. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV. Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol. 2008; 324:149–165. [PubMed: 18481459]

154. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168–1174. [PubMed: 20643915]

155. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587–2599. [PubMed: 21091279]

Table 1

Humanized mouse models and topical listing of HIV-related references.$^{\Delta}$

Mouse Strain / Humanized Mouse	CD34$^+$ TRANSPLANTED HUMANIZED MICE			
	DKO*	NOG*	NSG*	BLT$^\#$
In vivo HIV replication and pathogenesis	• Baenziger, 2006 • Berges, 2006 • An, 2007 • Gorantla, 2007 • Zhang, 2007 • Berges, 2008 • Hofer, 2008 • Jiang, 2008 • Van Duyne, 2008 • Berges, 2009 • Choudhory, 2009 • Ince, 2009 • Hofer, 2010 • Sango, 2010 • Neff, 2010 • Luo, 2010 • Neff, 2011	• Watanabe, 2007 (Blood)^ • Watanabe, 2007 (JVI)^ • Nie, 2009 • Sato, 2010 (JVI) • Sato, 2010 (Vaccine)	• Van Duyne, 2008 • Kumar, 2008 • Gorantla, 2010 (JI) • Gorantla, 2010 (AJP) • Holt, 2010 • Joseph, 2010̂ • Dash, 2011	• Sun, 2007 • Denton, 2008 • Brainard, 2009 • Denton, 2010 • Kim, 2010 • Garg, 2011
Human anti-HIV responses	Humoral • Baenziger, 2006 ◆ • An, 2007 ⊗ • Gorantla, 2007 ⊗ • Ince, 2009 ⊗ Cellular • An, 2007 ⊗	Humoral • Sato, 2010 (Vaccine) ◆ • Watanabe, 2007 (Blood)^ ◆ APOBEC • Sato, 2010 (JVI) ◆	Cellular • Gorantla, 2010 (JI) Ψ	Humoral • Sun,2007 Ψ • Brainard, 2009 Ψ Cellular • Brainard, 2009 Ψ
HIV therapy	ART • Choudhory, 2009 • Sango, 2010 *tat*-derived peptides • Van Duyne, 2008 Neutralizing Ab • Luo, 2010 aptamer delivered siRNA	Not Evaluated	*tat*-derived peptides • Van Duyne, 2008 T-cell directed siRNA • Kumar, 2008 Zinc-finger Nuclease • Holt, 2010 Neutralizing Ab	T-cell directed siRNA • Kim, 2010

Mouse Strain / Humanized Mouse	CD34+ TRANSPLANTED HUMANIZED MICE			
	DKO*	NOG*	NSG*	BLT#
	• Neff, 2011		• Joseph, 2010Ô	
Mucosal HIV transmission	Vaginal • Berges, 2008 • Neff, 2010 Rectal • Berges, 2008 • Hofer, 2008	Not Evaluated	Not Evaluated	Vaginal • Denton, 2008 Rectal • Sun, 2007 • Denton, 2010
HIV prevention	Vaginal • Neff, 2010	Not Evaluated	Not Evaluated	Vaginal and Rectal • Denton, 2008 • Denton, 2010 Intravenous • Denton, 2010

*Δ*Note that some papers covered multiple topics and therefore are repeated under the various appropriate headings on the last 4 lines of the table.

*Unless indicated by the ^, mice were generated by the typical protocol where the CD34+ cell transplant was given to newborns.

Those entries marked ^ are studies in which the CD34+ cell transplant was given to adult mice.

#BLT mouse generation includes a Bone marrow transplant of CD34+ hematopoietic progenitor cells into NOD/SCID or NSG mice previously implanted with autologous fetal Liver and Thymus tissue.

⊗HIV-specific human immune responses were examined, but not detected.

◆HIV-specific human immune responses were occasionally detected.

ψHIV-specific human immune responses were consistently detected.

Table 2

Key characteristics of immunodeficient mouse strains most frequently used for humanization.

Parent Strain	Additional Mutation	Most commonly humanized strains	Strain Characteristics (from Shultz, et al. 2007)	Frequent labels for humanized mice of each strain
Rag2 Knockout mice	IL2 receptor gamma chainknockout	$BALB/c\text{-}Rag2^{null}\gamma c^{null}$	• Typical lifespan greater than 1 year • No mouse T, B, or NK cells • Radiation resistant	• double knockout or DKO-hu HSC • RAG-hu mice • HIS or "human immune system" mice
Non obese diabetic / Severe Combined Immuno-deficient	IL2 receptor gamma chain knockout	$NOD/SCID\gamma c^{null}$ (NOG: $NOD/Shi\text{-}scid\gamma c^{null}$) (NSG: $NOD/LtSz\text{-}scid/scid\gamma c^{null}$)	• Typical lifespan greater than 1 year • No mouse T, B, or NK cells • Radiation sensitive • Fewer stem cells required for engraftment	• NOG-hu HSC mice • NSG-hu HSC mice • NSG BLT mice
	→	$NOD/SCID$ (NOD/Shi-scid) (NOD/LtSz-scid/scid)	• Lifespan of ~1 year due to thymic lymphomas that develop in some animals • No mouse T or B cells / Reduced NK cell levels • Radiation sensitive • No human T cells develop in absence of human thy/liv implant	• BLT mice • N/S BLT mice